POY_1170x120_8-12-19

Sanofi

FDA approves asthma indication for Dupixent (dupilumab)

FDA approves asthma indication for Dupixent (dupilumab)

TARRYTOWN, N.Y. and PARIS — Regeneron Pharmaceuticals, Inc. and Sanofi today announced the U.S. Food and Drug Administration has approved Dupixent (dupilumab) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. Dupixent inhibits the overactive signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13),

Sanofi insulin savings program aims to cut costs

Sanofi insulin savings program aims to cut costs

BRIDGEWATER, N.J. — Sanofi’s new Insulins VALyou Savings Program will seek to help lower out-of-pocket costs for people living with diabetes who otherwise would pay full retail price for Lantus or Admelog. This includes certain uninsured patients who don’t qualify for traditional patient assistance programs, in addition to some commercially insured patients with a high

Sanofi to acquire Bioverativ for $11.6 billion

Sanofi to acquire Bioverativ for $11.6 billion

PARIS — Sanofi plans to buy biopharmaceutical company Bioverativ Inc. in a deal valued at $11.6 billion. Waltham, Mass.-based Bioverativ specializes in therapies for hemophilia and other rare blood disorders. Sanofi said Monday that the addition of Bioverativ will boost its presence in specialty care and leadership in rare diseases as well as provide an expansion platform

Sanofi cleared to market Admelog mealtime insulin

Sanofi cleared to market Admelog mealtime insulin

PARIS — Sanofi has received Food and Drug Administration approval for Admelog, described as the first follow-on insulin lispro to help people with diabetes manage blood sugar levels at mealtime. Sanofi said Monday that Admelog (insulin lispro injection, 100 units/ml) will be available in both vials and the SoloStar pen, which is the most-used disposable

ACT Kids adds toothpaste to oral care line

ACT Kids adds toothpaste to oral care line

BRIDGEWATER, N.J. — Sanofi has launched ACT Kids Toothpaste, complementing the ACT brand’s lineup of oral rinses for children. Sanofi said Monday that ACT Kids Toothpaste is an anti-cavity fluoride toothpaste specially designed for children ages 2 and older. The toothpaste strengthens and protects developing teeth and helps prevent cavities. With ACT Kids Toothpaste’s Bubble

Sanofi cleared to market OTC Xyzal allergy medicine

Sanofi cleared to market OTC Xyzal allergy medicine

BRIDGEWATER, N.J. — Sanofi is adding to its roster of prescription-to-OTC allergy medications with Xyzal Allergy 24HR. The Food and Drug Administration has approved Xyzal Allergy 24HR (levocetirizine dihydrochloride) as an over-the-counter treatment to alleviate symptoms of seasonal and year-round allergies, Sanofi said Wednesday. The product offers proven 24-hour relief from runny nose, sneezing, itchy

Sanofi launches Soliqua 100/33 insulin pen

Sanofi launches Soliqua 100/33 insulin pen

PARIS — Sanofi has released Soliqua 100/33, an insulin injection for type 2 diabetes, to U.S. pharmacies. The company said Wednesday that Soliqua 100/33 (insulin glargine 100 units/ml and lixisenatide 33 mcg/ml) comes in a single, prefilled SoloStar pen with a dosage range of 15 to 60 units and two starting doses to support patients’

Sanofi names Main to lead new consumer health unit

Sanofi names Main to lead new consumer health unit

PARIS — Sanofi has appointed former Bayer executive Alan Main as executive vice president of its newly formed Consumer HealthCare global business unit. Sanofi said Friday that Main, who also joins its executive committee, will be responsible for building and maintaining the company’s position in the consumer health care market, including the expected integration of

Sanofi cleared by FDA to market Adlyxin

Sanofi cleared by FDA to market Adlyxin

PARIS — Sanofi has gained Food and Drug Administration approval for Adlyxin (lixisenatide), a medication for type 2 diabetes. A once-daily mealtime GLP-1 receptor agonist injection, Adlyxin is indicated as an adjunct to diet and exercise for improving blood glucose control in the treatment of adults with type 2 diabetes.Sanofi said this week that Adlyxin

Sanofi, Boehringer agree to $25 billion asset swap

Sanofi, Boehringer agree to $25 billion asset swap

PARIS — Sanofi has agreed to a 22.8 billion euro ($25.1 billion) asset swap with Germany’s Boehringer Ingelheim GmbH that will boost the French drug manufacturer’s business in selling over-the-counter drugs. The two companies reached a definitive agreement late Monday after announcing exclusive negotiations in December. Terms are unchanged from the original announcement: Sanofi will

Sanofi, Boehringer Ingelheim mull business swap

Sanofi, Boehringer Ingelheim mull business swap

NEW YORK — Sanofi and Boehringer Ingelheim are in talks to swap their animal health and consumer health care businesses, respectively. The companies said Tuesday that the proposed transaction would involve an exchange of Sanofi’s Merial animal health business (“Merial”), valued at €11.4 billion ($12.45 billion U.S.), and Boehringer Ingelheim’s consumer health care business,valued at €6.7 billion ($7.32 billion U.S.).

Sanofi, Google team up to improve diabetes care

Sanofi, Google team up to improve diabetes care

PARIS and MOUNTAIN VIEW, Calif. — Sanofi and the life sciences team at Google have formed a collaboration to improve care and outcomes for people with type 1 and type 2 diabetes. The companies said the alliance will pair Sanofi’s leadership in diabetes treatments and devices with Google’s expertise in analytics, miniaturized electronics and low-power chip